Novabay Pharmaceuticals shares are trading higher after the company received the right to commercialize amniotic tissue allograft from Biostem Technologies, which is intended for use as a protective covering during the repair of ocular surfaces.
Portfolio Pulse from Benzinga Newsdesk
Novabay Pharmaceuticals has granted Biostem Technologies the right to commercialize Amniotic Tissue Allograft, a product intended for use as a protective covering during the repair of ocular surfaces. This has led to a rise in Novabay's share prices.
September 11, 2023 | 12:24 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Novabay's decision to grant commercialization rights to Biostem Technologies has led to a rise in its share prices.
The news directly pertains to Novabay Pharmaceuticals and its decision to grant commercialization rights for its product to Biostem Technologies. This decision is likely to have a positive impact on the company's revenues and, consequently, its share prices.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100